Build Life‑Science Scale in the United States.

The United States is the world’s largest pharmaceutical market—valued at US $634 billion in 2024 and projected to reach nearly US $884 billion by 2030. With deep capital pools, unrivalled R&D infrastructure, and a gold‑standard regulator, it remains the launch‑pad of choice for breakthrough therapeutics and advanced manufacturing.

Flexible Partnership Models.

Select the structure that aligns with your capital plan:

• Leasing – operating leases to suit your needs.

• Project Finance – milestone-based funding that scales with your pipeline.

• Rent-to-Own – build equity in critical facilities while you innovate.

Who We Serve.

• Global and domestic pharmaceutical companies scaling clinical or commercial production.

• Public and private research institutes driving next-generation biologics.

• Leading universities advancing translational science and talent development.

Why the USA?

• Premier bio‑clusters such as Boston/Cambridge, North Carolina’s Research Triangle and the San Francisco Bay Area lead national rankings for patents, NIH funding, and venture capital.

• Generous incentives – a federal R&D tax credit of up to 20 % on incremental qualified research expenses, with additional state‑level programs.

• BARDA & federal funding – multi‑billion‑dollar initiatives like Project NextGen (US $5 bn) accelerate vaccine and biologics development and support advanced manufacturing technologies.

• Regulatory prestige – FDA approvals open doors to global markets, reinforcing quality and patient trust worldwide.

• Deep talent pool – the U.S. attracts top scientists and engineers, supported by >US $48 bn in annual NIH funding and a vibrant venture ecosystem.

Let’s Advance Health—Together.

Whether you’re planning a green‑field build, expanding capacity, or setting up a collaborative lab, our team is ready to make your vision a reality. Contact us today to explore how an American footprint can power your next breakthrough.